Pathogen Identification in Complex Biological Fluids

Abstract

Provided herein are methods for rapidly identifying a microbe, such as a pathogen, from a biological sample including, blood, urine, wound effluent, stool, serum, and bronchoalveolar lavage fluid. The method comprises obtaining the sample from the subject and performing a spectrometric analysis of the lipids in the microbe to obtain a profile. The profile obtained is compared with a molecular mass lipid profile of known microbes for identification. Also provided is a method for identifying one or more antimicrobial drugs effective to treat a microbial strain in a subject.

Description

BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates generally to the field of medicine and clinical microbiology. In particular, the invention relates to a diagnostic method for rapid identification of pathogenic species from complex biological fluids.

Description of the Related Art

Clinicians need to rapidly and accurately identify pathogens during life-threatening infections. Current methods require culturing microorganisms, such as bacteria on solid medium to obtain a pure colony and usually requires multiple rounds of replication to permit diagnosis, which can often require significant time. However, there are critical failings due to the inability to differentiate closely related species or multiple organisms from complex biological fluids. There is clearly a need for a rapid method which allows for rapid assay and identification of microorganisms, such as bacteria and fungi, from complex fluids without the need to grow the organisms out on differential and complex media, a process often requiring several days before identification of the microorganism species can be accurately ascertained.

It would be beneficial, therefore, to find a method that allows for rapid (within hours) and accurate identification of a variety of microorganisms such as Gram-positive and Gram-negative bacteria and fungi, from clinically relevant samples by mass spectrometry for lipid analysis of the different pathogen types. The prior art is deficient in this respect. The present invention fulfills this longstanding need and desire in the art.

SUMMARY OF THE INVENTION

The present invention is directed to a method for rapidly identifying a microbe. This method comprises obtaining a biological sample from a subject and determining, via spectrometry, a molecular mass profile of microbial lipids either extracted from the microbe or from microbial cells. The molecular mass profile of the lipids from the microbe is compared with the molecular mass profile of lipids from a known microbe. An identical profile indicates the identity of the microbe in the biological sample. The present invention is directed to a related method that further comprises isolating the microbe from the biological sample.

The present invention also is directed to a method for rapidly identifying a pathogenic bacterium in a blood sample. This method comprises obtaining the blood sample from a subject and extracting lipids from the bacterial pathogen at zero passage. The molecular mass profile of the extracted lipids is determined via spectrometry. The molecular mass profile of the extracted lipids is compared with the molecular mass profile of lipids from a known pathogenic bacterium. An identical profile indicates the identity of the pathogenic bacterium. The present invention is directed to a related method that further comprises isolating the pathogenic bacterium from the biological sample.

The present invention is directed further to a method for identifying one or more antimicrobial drugs effective to treat a microbial strain in a subject in need of such treatment. This method comprises obtaining a blood sample from the subject and extracting lipids from microbes in the sample. A spectrographic analysis of the extracted lipids is performed to obtain a molecular mass profile thereof. The extracted lipids profile are compared with a library of known lipid profiles of strains of pathogenic microbes to identify the strain of pathogenic microbe in the biological sample followed by identifying one or more antimicrobial drugs effective to treat the identified microbial strain.

Other and further aspects, features, benefits, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others that will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof that are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

FIG. 1 illustrates the strategy of mass spectrometric analysis of Escherichia coli lipid A from blood bottles.

FIGS. 2A-2H shows E. coli inoculated into blood bottles detected by MALDI-TOF analysis of lipid A. FIG. 2A shows E.coli W3110 grown in nutrient rich medium. FIG. 2B shows E.coli W3110 grown in a blood bottle for 24 hours at 37° C. FIG. 2C shows E. coli W3110 grown in a blood bottle for 2 hours at 37° C. and sampled with differential centrifugation. FIG. 2D shows E. coli W3110 inoculated at 10⁸ CFU/mL in a blood bottle and grown for 4 hours at 37° C. FIG. 2E shows E. coli W3110 inoculated at 10⁶ CFU/mL in a blood bottle and grown for 6 hours at 37° C. FIG. 2F shows E. coli W3110 inoculated at 10⁶ CFU/mL in a blood bottle and grown for 24 hours at 37° C. FIG. 2G shows E. coli W3110 inoculated at 10⁸ CFU/mL in an aerobic blood bottle with neutralization resin. FIG. 2H shows E. coli W3110 inoculated at 108 CFU/mL in pediatric blood bottle with neutralization resin.

FIG. 3 shows the mass spectrometric analysis of pathogenic species of Pseudomonas aeruginosa PAO1 done in O+ blood sample.

FIGS. 4A-4B shows the mass spectrometric analysis of Acinetobacter baumannii done in blood sample. FIG. 4A shows the mass spectrometric analysis of Acinetobacter baumannii in standard aerobic bottles ˜10¹ intial inoculum at t₆. FIG. 4B shows the mass spectrometric analysis of Acinetobacter baumannii in standard aerobic bottles ˜10⁶ intial inoculum cells at t₆

FIGS. 5A-5D shows the mass spectrometric analysis of Staphylococcus aureus done in blood sample. FIG. 5A shows the mass spectrometric analysis of Staphylococcus aureus MRSA M2 in standard aerobic bottle at ˜10¹ intial inoculum at 24 hours (t₂₄). FIG. 5B shows the mass spectrometric analysis of Staphylococcus aureus MRSA M2 in standard aerobic bottle at ˜10⁷ intial inoculum at t₂₄. FIG. 5C shows the mass spectrometric analysis of Staphylococcus aureus MRSA M2 in standard anaerobic bottle at ˜10⁷ intial inoculum at t₂₄. FIG. 5D shows the mass spectrometric analysis of Staphylococcus aureus MRSA NRS123 in standard anaerobic bottle at ˜10⁸ intial inoculum at t₂₄.

FIG. 6 shows the mass spectrometric analysis of Klebsiella pneumoniae B6 in standard aerobic bottle at ˜10⁸ intial inoculum at t₆.

FIGS. 7A-7R show the mass spectrometric analysis of pathogenic species done in urine. FIG. 7A shows the mass spectrometric analysis of Arthrobacter pigmenti. FIG. 7B shows the mass spectrometric analysis of Bacillus cereus. FIG. 7C shows the mass spectrometric analysis of Bacillus pumilus. FIG. 7D shows the mass spectrometric analysis of Brevundimonas diminuta. FIG. 7E shows the mass spectrometric analysis of Candida albicans. FIG. 7F shows the mass spectrometric analysis of Enterococcus faecalis. FIG. 7G shows the mass spectrometric analysis of Exiguobacterium. FIG. 7H shows the mass spectrometric analysis of Micrococcus luteus. FIG. 7I shows the mass spectrometric analysis of Moraxella osloensis. FIG. 7J shows the mass spectrometric analysis of Paenibacillus lautus. FIG. 7K shows the mass spectrometric analysis of Pseudomonas oryzihabitans. FIG. 7L shows the mass spectrometric analysis of Pseudomonas stutzeri. FIG. 7M shows the mass spectrometric analysis of Rhodococcus opacus. FIG. 7N shows the mass spectrometric analysis of Roseomonas mucosa. FIG. 7O shows the mass spectrometric analysis of Rothia amarae. FIG. 7P shows the mass spectrometric analysis of Staphylococcus aureus. FIG. 7Q shows the mass spectrometric analysis of Staphylococcus capitis. FIG. 7R shows the mass spectrometric analysis of Staphylococcus cohnii.

FIG. 8 shows the mass spectrometric analysis of one E.coli fecal pellet incubated overnight in liquid medium.

FIG. 9 shows the mass spectrometric analysis of Francisella species done in rich medium, wound effluent, bronchoalveolar lavage fluid and serum.

DETAILED DESCRIPTION OF THE INVENTION

As used herein in the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one.

As used herein “another” or “other” may mean at least a second or more of the same or different claim element or components thereof. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. “Comprise” means “include.”

As used herein, the term “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term “about” generally refers to a range of numerical values (e.g., +/−5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.

As used herein, the terms “microbe” and “microorgansim” are interchangeable and includes pathogenic, non-pathogenic and commensal organisms, such as, but not limited to, bacteria, viruses, protozoas, and fungi.

As used herein, the phrase “zero passage” refers to the culture before medium replacement. The cells are grown for a period of time in one dish. When the cells are transferred to a second dish the cells are considered to be passaged. The first plating of cells is considered to be zero passage. For the purposes of this invention, “zero passage” also refers to extraction of lipids from microbes or analyzing lipids from whole microbial cells comprising a sample, particularly a blood sample, without first culturing the microbes for any period of time.

In one embodiment of the invention, there is provided a method for rapidly identifying a microbe, comprising obtaining a biological sample from a subject; determining, via spectrometry, a molecular mass profile of microbial lipids; and comparing the molecular mass profile of the lipids from the microbe with a molecular mass profile of lipids from a known microbe wherein an identical profile indicates the identity of the microbe in the biological sample.

Further to this embodiment the method comprises isolating the microbe from the biological sample. In an aspect of both embodiments the determining step may comprise extracting lipids from the microbe prior to the spectrometry; or performing spectrometry on microbial cells. The extracting step may comprise hydrolyzing the pathogenic cells by heat assisted mild acid hydrolysis.

Also in both embodiments the spectrometry may be mass spectrometry, tandem mass spectrometry (MS/MS) including multiple reaction monitoring and linked scans or ion mobility spectrometry (IMS). Representative types of mass spectrometry include, but are not limited to, matrix-assisted laser desorption/ionization-time-of-flight mass spectrometer (MALDI-TOF MS), Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS), ion trap, quadrupole, magnetic sector, Q-TOF, or triple quadrupole, platforms, tandem MS, infusion-based electro spray ionization (ESI) coupled to ion trap tandem mass spectrometry (ITMSⁿ), surface acoustic wave nebulization (SAWN) technology, including SAWN on any mass analyzer (e.g. quadrupole TOF-MS (QTOF) or SAWN-ion trap (IT) MS).

In addition, the lipid may be lipid A, Lipoteichoic Acid, a glycolipid, or cardiolipin. Furthermore, the microbe may be a pathogen, a non-pathogen or a commensal bacterium. Representative types of pathogens which may be detected using this method include but are not limited to Acinetobacter, Actinomyces, Arthrobacter, Burkholderia, Bacillus, Bacteroides, Bordetella, Borrelia, Brevundimonas, Brucella, Candida, Clostridium, Corynebacterium, Campylobacter, Deinococcus, Escherichia, Enterobacter, Enterococcus, Erwinia, Eubacterium, Exiguobacterium, Flavobacterium Francisella, Gluconobacter, Helicobacter, Intrasporangium, Janthinobacterium, Klebsiella, Kingella, Legionella, Leptospira, Mycobacterium, Moraxella, Micrococcus, Neisseria, Oscillospira, Proteus, Pseudomonas, Providencia, Paenibacillus, Rickettsia, Rhodococcus, Roseomonas, Rothia, Salmonella, Serratia, Staphylococcus, Shigella, Spinillum, Streptococcus, Stenotrophomonas Treponema, Ureaplasma, Vibrio, Wolinella, Wolbachia, Xanthomonas, Yersinia, and Zoogloea.

In a non-limiting aspect of these embodiments, the microbe is a Gram-negative bacterium and the lipid is lipid A, a glycolipid or cardiolipin. In another non-limiting aspect the microbe is a Gram-positive bacterium and the lipid is Lipoteichoic Acid, a glycolipid or cardiolipin. In yet another non-limiting aspect, the microbe may be a fungus and the lipid may be a glycolipid or cardiolipin or other fungal lipid. In all embodiments and aspects thereof representative biological samples include, but are not limited to, blood, urine, stool, serum, wound effluent or bronchoalveolar lavage fluid.

In another embodiment of the invention, there is provided a method for rapidly identifying a pathogenic bacterium in a blood sample comprising obtaining the blood sample from a subject; extracting lipids from the bacterial pathogen at zero passage; determining, via spectrometry, a molecular mass profile of the extracted lipids; and comparing the molecular mass profile of the extracted lipids with a molecular mass profile of lipids from a known pathogenic bacterium wherein an identical profile indicates the identity of the pathogenic bacteria.

Further to this embodiment the method comprises isolating the pathogenic bacterium from the blood sample. In this further embodiment, the isolating step may comprise separating the pathogenic bacterial cells from human cells via a low speed centrifugation. In both embodiments the extracting step may comprise hydrolyzing the pathogenic cells by a heat assisted mild acid hydrolysis.

In both embodiments the spectrometry may be mass spectrometry, a tandem mass spectrometry or ion mobility spectrometry. Particular types of spectrometry are as described supra.

In one aspect, the pathogenic bacterium is a Gram-negative bacterium and the lipid may be lipid A, a glycolipid or cardiolipin. In another aspect, the pathogen is a

Gram-positive bacterium and the lipid may be Lipoteichoic Acid, a glycolipid or cardiolipin. Representative types of pathogens which may be detected using this method include, but are not limited to, Acinetobacter, Actinomyces, Arthrobacter, Burkholderia, Bacillus, Bacteroides, Bordetella, Borrelia, Brevundimonas, Brucella, Candida, Clostridium, Corynebacterium, Campylabacter, Deinococcus, Escherichia, Enterobacter, Enterococcus, Erwinia, Eubacterium, Exiguobacterium, Flavobacterium, Francisella, Gluconobacter, Helicobacter, Intrasporangium, Janthinobacterium, Klebsiella, Kingella, Legionella, Leptospira, Mycobacterium, Moraxella, Micrococcus, Neisseria, Oscillospira, Proteus, Pseudomonas, Providencia, Paenibacillus, Rickettsia, Rhodococcus, Roseomonas, Rothia, Salmonella, Serratia, Staphylococcus, Shigella, Spirillum, Streptococcus, Stenotrophomonas Treponema, Ureaplasma, Vibrio, Wolinella, Wolbachia, Xanthomonas, Yersinia, and Zoogloea.

In yet another embodiment of the invention, there is provided a method for identifying one or more antimicrobial drugs effective to treat a microbial strain in a subject in need of such treatment, comprising obtaining a biological sample from the subject, extracting lipids from the pathogenic microbe comprising the sample, performing a spectrographic analysis of the extracted lipids to obtain a molecular mass profile thereof, comparing the extracted lipids profile with a library of known lipid profiles of strains of pathogenic microbes to identify the strain of pathogenic microbe in the biological sample and identifying one or more antimicrobial drugs effective to treat the identified microbial strain.

In this embodiment the performing step comprises analysis via mass spectrometry, a tandem mass spectrometry or ion mobility spectrometry as described. Representative types of mass spectrometry are as described supra. Also in the method described supra the spectrographic analysis of lipids differentiates among pathogenic microbes at the genus, species, sub-species or strain level.

In this embodiment, the pathogenic microbe is a Gram-negative bacterium, a Gram-positive bacterium or a fungus. Also in aspects of this embodiment, the Gram-negative bacterial lipid may be lipid A, a glycolipid or cardiolipin, the Gram-positive bacterial lipid may be Lipoteichoic Acid, a glycolipid or cardiolipin and the fungal lipid may be a glycolipid precursor of one or both of lipid A or Lipoteichoic Acid or a cardiolipin. Representative biological samples include, but are not limited to, blood, urine, stool, serum, wound effluent, or bronchoalveolar lavage fluid.

Provided herein are methods for rapidly identifying a variety of microbes from biological samples. This method has significant utility for accurately and rapidly identifying closely related pathogens during life threatening infections which circumvents the need to culture an organism to obtain sufficient amounts for analysis and/or testing or to ensure purity. The methods described herein produce an identification within hours rather than days, allowing for better antibiotic and antifungal stewardship. Moreover, these methods are useful to obtain information on antibiotic resistance markers depending on the pathogenic background, which can be used to inform therapeutic treatment.

Generally, the method comprises obtaining a biological sample from a subject and determining via spectrometry or performing a spectrometric analysis of the microbial lipids. Optionally, the microbe may be isolated from the sample or, alternatively, the whole microbial cell may be analyzed. For example, lipid analysis may utilize, but is not limited to, mass spectroscopic methods detailed and described in U.S. Pat. No. 9,273,339, the entirety of which is hereby incorporated by reference. The microbe in the sample is identified by comparing the molecular mass spectrometric profile of the microbial lipid(s) with a library of known microbial mass spectrometric profiles such as those described in U.S. Pat. No. 9,273,339.

Spectrometric analysis may be performed on lipids extracted and isolated from or on whole cells of Gram-negative bacteria, Gram-positive bacteria, either aerobic or anaerobic, and fungi, particularly fungal pathogens, with discrimination among strains with a high degree of identify or similarity, such as those identified in Table 1. Particularly, mass spectrometric analysis may be performed on lipids of one or more pathogens in a blood sample with zero passage culturing. The method is accurate for detecting as few as 10¹-10⁹ pathogenic cells present in the sample. Non-limiting examples of microbial lipids are lipid A, Lipoteichoic acid, a glycolipid, such as, but not limited to, glycolipid precursors of the lipid A and/or Lipoteichoic acid, a cardiolipin, glycolipids, cardiolipin, or sphingolipids, glycerolipids, glycerophospholipids, sterol lipids, prenol lipids, polyketides, etc. or combinations thereof.

As described herein, generally spectrometric methods may comprise mass spectrometry, a tandem mass spectrometry (MS/MS) including multiple reaction monitoring and linked scans or ion mobility spectrometry as are well known in the art. Particularly, ion mobility spectrometry is useful for multiple reaction monitoring. As a type or subset of tandem mass spectrometry, IMS enables organism specific mass channel assays where all m/z channels are no longer scanned. Only those channels where the organisms specific signature ions are expected to be found are scanned. Alternatively, linked scans, another type or subset of tandem mass spectrometry, enables a specific analysis for only certain kinds of lipids by observing their functional groups by tandem MS.

Also provided is a method for identifying one or more antimicrobial drugs effective to treat a microbial strain. The methods described herein enable a high level of discrimination among similar and related pathogens. One particular strain can be identified in a patient sample thereby enabling a treatment protocol to be planned for the subject best suited to treat the identified pathogenic microbe. This is particularly useful against antibiotic-resistant strains, such as methicillin resistant Staphylococcus aureus and acquired polymyxin resistant Klebsiella spp., Pseudomonas spp. and Acinetobacter spp. or naturally resistant Proteus spp., Serratia spp. and Burkholderia spp. Because the results are rapidly obtained without having to culture the sample, a subject can be monitored for acquisition of opportunistic pathogens.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. Embodiments of the present invention are better illustrated with reference to the Figure(s), however, such reference is not meant to limit the present invention in any fashion.

EXAMPLE 1

Blood Culture Growth of Microorganisms and Micro-extraction of Lipid A, Lipoteichoic Acid, Glycolipids and/or Cardiolipin for Mass Spectrometry Analysis

Sterile blood is obtained from the University of Maryland Medical Center (UMMC) blood bank and is stored at 4° C. upon receipt. Commercial blood culture bottles are available for aerobic, anaerobic or slow-growing organisms or contain specialized additives for antibiotic neutralization or blood cell lysis. For purposes of performing the method, different blood cultures bottles can be used including, but not limited to, bottles manufactured by Becton Dickinson and Company (BD) and BioMerieux. Moreover, any of a variety of culture media used to support the growth of Gram-positive and Gram-negative bacteria, including aerobes and anaerobes, can be utilized in this method.

Preparation of 1M Ammonium Hydroxide Solution

Add 3.89 mL of 0.9 g/mL ammonium hydroxide to 96.1 mL endotoxin free H₂O for 100 mL of 1M Ammonium hydroxide.

Preparation of Blood Culture (Day 1)

Remove the flip-off cap from the blood culture (BC) bottle and swab the septum with alcohol. Use a 10 mL syringe with a 26G blunt tip needle to draw 5-10 mL blood from blood bag. Invert syringe and switch needle for Vacutainer holder to transfer blood to blood culture bottle. The vacuum of the bottle should pull the blood in without having to depress the plunger; this ensures that the bottle hasn't been compromised. Use a 1 mL syringe to transfer bacterial inoculums into blood culture bottle either directly from liquid culture grown overnight or diluted appropriately in rich media. Grow at 37° C. with shaking immediately after inoculation.

Sampling and Processing of Blood Culture Bottle (Day 1)

Use a 1-5 mL syringe to remove 1-2 mL culture at set time points. Swab septum with alcohol each time. Transfer it to 2 mL sterile microcentrifuge tube and spin tubes at 1100 rpm for 10 minutes. This pellets the human blood cells. Optionally transfer a small volume to a 96-well tissue culture plate to prepare serial dilutions in phosphate buffer saline (PBS) and to plate in triplicate on a lysogenic broth (LB) agar plate for enumeration. Transfer the supernatant to a 1.7 mL screw-cap tube and spin tube at 4000 rpm for 10 minutes. This pellets bacterial cells. Discard supernatant. Bacterial pellets are frozen at −20° C. or extracted immediately.

Ammonium Isobutyrate Extraction of Glycolipids (Day 1)

Thaw the pellet and resuspend the wet pellet with 400 μL of a 5:3, v/v, 70% isobutyric acid:1M ammonium hydroxide solution (250 μL of isobutyric acid+150 μL Ammonium hydroxide). Incubate at 100° C. for 30-45 minutes with vortexing every ˜15 min (performed in fume hood). Cool the tube on ice and centrifuge at 2,000×g for 15 min. Remove the supernatant to a new tube with 400 μL endotoxin free water (1:1 v/v), put on the surrogate cap with a hole poked into the top to allow sublimation, then freeze and lyophilize overnight. Lyophilization generates a fluffy, white pellet (1).

Processing of Extracts and MS Analysis (Day 2)

Wash sample with 1 mL of methanol, sonicate to resuspend and disrupt micelles, 5 minutes or more. Centrifuge at 10,000×g for 5 minutes, carefully aspirate methanol. Wash again with methanol. Solubilize and extract Lipid A in 25-190 μL of 3:1.5:0.25, v/v/v, chloroform:methanol:water, i.e. 120/60/10 μL. Vortex well. Optionally, add about 5 grains of Dowex 50WX8 (H+) and vortex well to desalt (e.g. Ca2+, Mg2+, and Na+). This enhances negative mode MALDI-MS sensitivity. Vortex and centrifuge at 8,000×g for 5 minutes. Spot 1 μL onto the MALDI target plate, followed by 1 μL of fresh matrix, for example, 10 [mg/mL] norharmane in 2:1, v/v, chloroform:methanol). Mass spectra are recorded in negative ion mode at 60-70% laser intensity and 900 laser shots per spectrum using a Bruker Microflex LRF MALDI-TOF (2) (FIGS. 1-6).

FIG. 1 shows the strategy of mass spectrometric analysis of Escherichia coli lipid A from blood bottles. FIGS. 2A-2H shows MALDI-TOF analysis of Escherichia coli lipid A extracted using differential centrifugation. Analysis of mass spectra was used to demonstrate the ability of lipid A and Lipoteichoic Acid to distinguish not only bacteria, but also antiobiotic resitance (for example, Methicillin-resistant Staphylococcus aureus (MRSA-M2) and Network on Antimicrobial Resistance in Staphylococcus aureus (MRSA-NRS123) FIGS. 5A-5D) and environmental variants (P.aeruginosa; FIG. 3) at high sensitivity, accuracy and specificity. The method of present invention accurately differentiated between different strains of species as shown in FIGS. 5A & 5D the mass spectra of Methicillin-resistant Staphylococcus aureus (MRSA-M2) and Staphylococcus aureus (MRSA-NRS123) shows different mass peak in hundredths and thousandths. The method of the present invention may be used for accurate distinction of species with as few as 10¹ bacterial cells to 10⁸ bacterial cells in the sample (FIGS. 4A-4B; FIGS. 5A-5C). The present method also differentiates antibiotic resistant species Acinetobacter baumannii and Klebsiella pneumoniae which have only subtle structural change in their lipid A (FIGS. 4A-4B & FIG. 6).

EXAMPLE 2

Isolation of Microorganisms from Urine and Micro-Extraction of Lipid A and Lipoteichoic Acid for Mass Spectrometry Analysis

Urine specimens are obtained from the University of Pittsburgh Medical Center and processed immediately or stored at −20° C. upon receipt.

Preparation of 1M Ammonium Hydroxide Solution

Add 3.89 mL of 0.9 g/mL ammonium hydroxide to 96.1 mL of endotoxin free H₂O for 100 mL of 1M Ammonium hydroxide.

Preparation of Urine Specimens (Day 1)

Transfer 5-10 mL of the specimen to a 15 mL conical tube and spin the tube at 4000 rpm for 10 minutes. This pellets the cells. Discard the supernatant. Pellets are frozen at −20° C. or are extracted immediately.

Ammonium Isobutyrate Extraction of Glycolipids (Day 1)

Thaw the pellet and resuspend the wet pellet with 400 μL of a 5:3, v/v, 70% isobutyric acid:1M ammonium hydroxide solution. Transfer to a 1.7 mL screw-cap tube (250 μL of isobutyric acid+150 μL Ammonium hydroxide). Incubate at 100° C. for 30-45 minutes with vortexing every ˜15 min (performed in a fume hood). Cool the tube on ice and centrifuge for at 2,000×g for 15 min. Remove the supernatant to a new tube with 400 μL endotoxin free water (1:1 v/v), put on a surrogate cap with a hole poked into the top to allow sublimation, then freeze and lyophilize overnight. Lyophilization generates a fluffy, white pellet (1).

Processing of Extracts and MS Analysis (Day 2)

Wash the sample with 1 mL of methanol, sonicate to resuspend and to disrupt the micelles, 5 minutes or more. Centrifuge at 10,000×g for 5 minutes, carefully aspirate the methanol. Wash again with methanol. Solubilize and extract Lipid A in 25-190 μL of 3:1.5:0.25, v/v/v, chloroform:methanol:water, i.e., 120/60/10 μL. Vortex well. Optionally add ˜5 grains of Dowex 50WX8 (H+) and vortex well to desalt (e.g. Ca2+, Mg2+, and Na+). This enhances negative mode MALDI-MS sensitivity. Vortex and centrifuge at 8,000×g for 5 minutes. Spot 1 μL on a MALDI target plate, followed by 1 μL fresh matrix, e.g., 10 [mg/mL] norharmane in 2:1, v/v, chloroform:methanol. Mass spectra are recorded in negative ion mode at 60-70% laser intensity and 900 laser shots per spectrum using a Bruker Microflex LRF MALDI-TOF (2) (FIGS. 7A-7R).

FIGS. 7A-7R shows representative examples of mass spectra of closely related Gram-positive bacteria, Gram-negative bacteria and fungus, differentiating them on the basis of different molecular mass profile of lipid A, Lipoteichoic Acid or glycolipid in urine sample. The method of present invention was used to accurately differentiate between closely related species of, for example, Pseudomonas and Staphylococcus in urine sample. The mass analysis accurately differentiated the lipid A mass profile of gram negative Pseudomonas oryzihabitans and Pseudomonas stutzeri, both having different mass peaks (FIGS. 7K-7L). Similarly, Gram-positive Staphylococcus species were differentiated by their different Lipoteichoic Acid mass profile (FIGS. 7P-7R).

EXAMPLE 3

Isolation of Microorganisms from Feces and Micro-Extraction of Lipid A and Lipoteichoic Acid for Mass Spectrometry Analysis

Murine fecal specimens are obtained from the lab of Dr. Hanping Feng at the University of Maryland, Baltimore and are processed immediately or are stored at −20° C. upon receipt.

Preparation of 1M Ammonium Hydroxide Solution

Add 3.89 mL of 0.9 g/mL ammonium hydroxide to 96.1 mL of endotoxin free H₂O for 100 mL of 1M ammonium hydroxide.

Preparation of Fecal Specimens (Day 1)

Transfer the specimen to a 2 mL sterile microcentrifuge tube and suspend it in 1×PBS. Don't fill the tube past 1 mL of volume. Use a tissue grinder pestle to disrupt the feces and to generate a slurry and spin the tube at 1100 rpm for 10 minutes. This pellets fecal debris and human cells. Transfer the supernatant to a 1.7 mL screw-cap tube and spin the tube at 4000 rpm for 10 minutes. This pellets the bacterial cells. Discard the supernatant. Pellets are frozen at −20° C. or are extracted immediately.

Ammonium Isobutyrate Extraction of Glycolipids (Day 1)

Thaw the pellet and resuspend the wet pellet with 400 μL of a 5:3, v/v, 70% isobutyric acid:1M ammonium hydroxide solution. Transfer to a 1.7 mL screw-cap tube (250 μL of isobutyric acid+150 μL ammonium hydroxide). Incubate at 100° C. for 30-45 minutes with vortexing every ˜15 min (performed in a fume hood). Cool the tube on ice and centrifuge at 2,000×g for 15 min. Remove the supernatant to a new tube with 400 μL endotoxin free water (1:1 v/v), put on a surrogate cap with a hole poked into the top to allow sublimation, freeze and lyophilize overnight. Lyophilization generates a fluffy, white pellet (1).

Processing of Extracts and MS Analysis (Day 2)

Wash the sample with 1 mL of methanol, sonicate to resuspend and to disrupt the micelles for 5 minutes or more. Centrifuge at 10,000×g for 5 minutes and carefully aspirate the methanol. Wash again with methanol. Solubilize and extract Lipid A in 25-190 μL of 3:1.5:0.25, v/v/v, chloroform:methanol:water, i.e. 120/60/10 μL. Vortex well. Optionally add ˜5 grains of Dowex 50WX8 (H+) and vortex well to desalt (e.g. Ca2+, Mg2+, and Na+). This enhances negative mode MALDI-MS sensitivity. Vortex and centrifuge at 8,000×g for 5 minutes. Spot 1 μL onto the MALDI target plate and follow with 1 μL fresh matrix, e.g. 10 [mg/mL] norharmane in 2:1, v/v, chloroform:methanol). Mass spectra are recorded in negative ion mode at 60-70% laser intensity and 900 laser shots per spectrum using a Bruker Microflex LRF MALDI-TOF (2). FIG. 8 shows the mass spectrometric analysis of E. coli in one fecal pellet incubated overnight in liquid medium.

EXAMPLE 4

Isolation of Microorganisms from Wound Effluent (WE), Bronchoalveolar Lavage Fluid (BAL), Serum and Micro-extraction of Lipid A and Lipoteichoic Acid for Mass Spectrometry Analysis

Preparation of 1M Ammonium Hydroxide Solution

Add 3.89 mL of 0.9 g/mL ammonium hydroxide to 96.1 mL of endotoxin free H₂O for 100 mL of 1M ammonium hydroxide.

Preparation of Wound Effluent, BAL, and Serum Specimens (Day 1)

Transfer 5-10 mL of the specimen to a 15 mL conical tube and spin the tube at 4000 rpm for 10 minutes. This pellets the cells. Discard the supernatant. Pellets are frozen at −20° C. or are extracted immediately.

Ammonium Isobutyrate Extraction of Glycolipids (Day 1)

Thaw the pellet and resuspend the wet pellet with 400 μL of a 5:3, v/v, 70% isobutyric acid:1M ammonium hydroxide solution. Transfer to a 1.7 mL screw-cap tube (250 μL of isobutyric acid+150 μL Ammonium hydroxide). Incubate at 100° C. for 30-45 minutes with vortexing every ˜15 min (performed in a fume hood). Cool the tube on ice and centrifuge for at 2,000×g for 15 min. Remove the supernatant to a new tube with 400 μL endotoxin free water (1:1 v/v), put on a surrogate cap with a hole poked into the top to allow sublimation, freeze and lyophilize overnight. Lyophilization generates a fluffy, white pellet (1).

Processing of Extracts and MS Analysis (Day 2)

Wash the sample with 1 mL of methanol, sonicate to resuspend and to disrupt micelles for 5 minutes or more. Centrifuge at 10,000×g for 5 minutes and carefully aspirate the methanol. Wash again with methanol. Solubilize and extract Lipid A in 25-190 μL of 3:1.5:0.25, v/v/v, chloroform:methanol:water, i.e. 120/60/10 μL. Vortex well. Optionally add ˜5 grains of Dowex 50WX8 (H+) and vortex well to desalt (e.g. Ca2+, Mg2+, and Na+). This enhances negative mode MALDI-MS sensitivity Vortex and centrifuge at 8,000×g for 5 minutes. Spot 1 μL onto the MALDI target plate and follow with 1 μL fresh matrix, e.g. 10 [mg/mL] norharmane in 2:1, v/v, chloroform:methanol) Mass spectra are recorded in negative ion mode at 60-70% laser intensity and 900 laser shots per spectrum using a Bruker Microflex LRF MALDI-TOF (2). FIG. 9 shows the mass spectrometric analysis of Francisella species done in rich medium, wound effluent, bronchoalveolar lavage fluid and serum.

EXAMPLE 5

Pathogenic Strains

Referring to Table 1 below, 520 isolates of pathogens were analyzed by the molecular mass profile of the lipids via mass spectrometry. The reference organisms presented in Table 1 include 32 of the most common bacterial species, 1 fungal species isolated from biological samples and 6 bacterial strains isolated from blood samples.

TABLE 1
LIST OF SPECIES FOR MS LIPID ANALYSIS
Species	Strain	Species	Strain
Enterococcus faecalis	FN1	Klebsiella pneumoniae	F1
Enterococcus faecalis	FN2	Klebsiella pneumoniae	S804263
Enterococcus faecalis	FN14	Klebsiella pneumoniae	T1173546
Enterococcus faecalis	FN39	Klebsiella pneumoniae	F28006
Enterococcus faecalis	FN45	Klebsiella pneumoniae	S7233
Enterococcus faecalis	FN46	Klebsiella pneumoniae	F87280
Enterococcus faecalis	FN59	Klebsiella pneumoniae	F3292636
Enterococcus faecalis	FN69	Klebsiella pneumoniae	X30374
Enterococcus faecalis	FN71	Klebsiella pneumoniae	M48525
Enterococcus faecalis	FN77	Klebsiella pneumoniae	S81517
Enterococcus faecium	M32517	Klebsiella pneumoniae	S83925
Enterococcus faecium	X7357	Klebsiella pneumoniae	H796922
Enterococcus faecium	T35657	Klebsiella pneumoniae	F900627
Enterococcus faecium	T23567	Klebsiella pneumoniae	S775008
Enterococcus faecium	W28461	Klebsiella pneumoniae	T1313002
Enterococcus faecium	W5454959	Klebsiella pneumoniae	S1428956
Enterococcus faecium	T5504515	Klebsiella pneumoniae	W2034211
Enterococcus faecium	S3899836	Klebsiella pneumoniae	A2 Obscure
Enterococcus faecium	H16150	Klebsiella pneumoniae	B3 Bright
Enterococcus faecium	M37969	Klebsiella pneumoniae	B3 Obscure
Staphylococcus aureus	NRS22	Klebsiella pneumoniae	B5
Staphylococcus aureus	NRS387	Klebsiella pneumoniae	B8
Staphylococcus aureus	NRS384	Klebsiella pneumoniae	C4
Staphylococcus aureus	NRS382	Klebsiella pneumoniae	D4
Staphylococcus aureus	NRS1	Klebsiella pneumoniae	D7
Staphylococcus aureus	M2	Klebsiella pneumoniae	E5
Staphylococcus aureus	NRS123	Klebsiella pneumoniae	F28006
Staphylococcus aureus	NRS385	Klebsiella pneumoniae	F8
Staphylococcus aureus	NRS100	Klebsiella pneumoniae	G7
Staphylococcus aureus	NRS484	Klebsiella pneumoniae	H4 Bright
Staphylococcus aureus	NRS72	Klebsiella pneumoniae	I1
Staphylococcus aureus	RN6390	Klebsiella pneumoniae	A5
Staphylococcus aureus	Seattle 1945	Klebsiella pneumoniae	B6
Staphylococcus aureus	RN4220	Klebsiella pneumoniae	B9
Staphylococcus aureus	8325-4	Klebsiella pneumoniae	C1
Staphylococcus aureus	M1	Klebsiella pneumoniae	C5
Klebsiella pneumoniae	F645516	Klebsiella pneumoniae	C6
Klebsiella pneumoniae	F892412	Klebsiella pneumoniae	C8
Klebsiella pneumoniae	T1019279	Klebsiella pneumoniae	D1
Klebsiella pneumoniae	S777647	Klebsiella pneumoniae	F1
Klebsiella pneumoniae	E2	Acinetobacter baumannii	ATCC C2B
Klebsiella pneumoniae	E6	Acinetobacter baumannii	ATCC 17978 WT
Pseudomonas putida	6732-1 oxidative (−)	Acinetobacter baumannii	AB0057
Klebsiella pneumoniae	F3292636	Acinetobacter baumannii	M537095; ColS
Klebsiella pneumoniae	F645516	Acinetobacter baumannii	S1444428; ColS
Klebsiella pneumoniae	F900627	Acinetobacter baumannii	2B3; H1905339
Klebsiella pneumoniae	H5	Acinetobacter baumannii	2C8; T1316530
Klebsiella pneumoniae	I2	Acinetobacter baumannii	1I5; X1329321
Klebsiella pneumoniae	I4	Acinetobacter baumannii	1I6; S1259244
Klebsiella pneumoniae	I6	Acinetobacter baumannii	2A7; W1910338
Escherichia coli	ATCC 43888	Salmonella minnesota	R595; ATCC
			49284
Salmonella typhimurium	CS339	Pseudomonas aeruginosa	BE-174
Burkholderia cenocepacia	ATCC 17759	Pseudomonas aeruginosa	BE-175
Genomovar I
Francisella novicida	U112	Pseudomonas aeruginosa	BE-176
Escherichia coli	BW25113	Pseudomonas aeruginosa	BE-177
Pseudomonas aeruginosa	PAK	Pseudomonas aeruginosa	BE-178
Burkholderia cenocepacia	CEP0790	Pseudomonas aeruginosa	BE-398
Burkholderia multivorans	ATCC 17616	Pseudomonas aeruginosa	BE-399
Genomovar II
Pseudomonas aeruginosa	H35N::PA1393	Pseudomonas aeruginosa	BE-400
Pseudomonas putida	ATCC 700007	Pseudomonas aeruginosa	BE-401
Stenotrophomonas	CF 2	Pseudomonas aeruginosa	BE-402
maltophilia
Yersinia pestis	KIM6−pCDI−pgm−	Enterobacter cloacae	FN2462
Yersinia pestis	KIM6+ (Bliska)	Enterobacter cloacae	FN2468
Francisella tularensis	LVS	Enterobacter cloacae	FN2475
holarctica
Pseudomonas fluorescens	ATCC BAA-477	Enterobacter cloacae	FN2486
Burkholderia cenocepacia	ATCC 17616	Enterobacter cloacae	FN2531
Genomovar II
Pseudomonas aeruginosa	H35N::PA1393	Enterobacter cloacae	FN2532
Pseudomonas putida	ATCC 700007	Enterobacter cloacae	FN2540
Stenotrophomonas	CF 2	Enterobacter cloacae	FN2541
maltophilia
Yersinia pseudotuberculosis	01:b	Enterobacter cloacae	FN2542
Yersinia enterocolitica	CS080	Enterobacter cloacae	FN2543
Acinetobacter baumannii	ATCC 19606	Enterobacter cloacae	YDC469-1
	WT colistin-
	sensitive
Acinetobacter baumannii	ATCC 19606	Enterobacter cloacae	YDC476
	WT colistin-
	resistant
Enterobacter cloacae	YSC506	Acinetobacter baumannii	M6142110
Enterobacter cloacae	YDC567	Acinetobacter baumannii	M6154841
Enterobacter cloacae	YDC572	Acinetobacter baumannii	T6236674
Enterobacter cloacae	YDC590	Acinetobacter baumannii	T6276391 # 1
Acinetobacter baumannii	T25987; ColS	Acinetobacter baumannii	T6276391 # 2
Enterobacter cloacae	YDC603	Acinetobacter baumannii	T6262055
Enterobacter cloacae	YDC612	Acinetobacter baumannii	S4372736 # 1
Enterobacter cloacae	YDC665	Acinetobacter baumannii	S4372736 # 2
Enterobacter cloacae	YDC673	Acinetobacter baumannii	T6292796
Acinetobacter baumannii	1H7; S906365	Acinetobacter baumannii	W6231191
Acinetobacter baumannii	1G5; F1918631	Acinetobacter baumannii	H6195648
Acinetobacter baumannii	1I7; W18065482	Acinetobacter baumannii	W6248513
Acinetobacter baumannii	2B9; T2796953	Acinetobacter baumannii	F6001181
Acinetobacter baumannii	2G3	Acinetobacter baumannii	F6005058
Acinetobacter baumannii	2A8; H1883446	Acinetobacter baumannii	S4409585
Acinetobacter baumannii	C8	Acinetobacter baumannii	T6345606
Acinetobacter baumannii	MU181	Acinetobacter baumannii	W6265964
Acinetobacter baumannii	MU215	Acinetobacter baumannii	T6337518
Pseudomonas aeruginosa	PAO1	Acinetobacter baumannii	X3967941
Acinetobacter baumannii	S4259384	Acinetobacter baumannii	T6374080
Acinetobacter baumannii	S4249014	Acinetobacter baumannii	M6307212
Acinetobacter baumannii	M6139359	Serratia marcescens	SM 3
Acinetobacter baumannii	S4217436	Serratia marcescens	SM 4
Acinetobacter baumannii	H6076944	Serratia marcescens	SM 5
Acinetobacter baumannii	M6138054	Serratia marcescens	SM 8
Acinetobacter baumannii	H6137766	Serratia marcescens	SM 9
Acinetobacter baumannii	S4393349	Serratia marcescens	SM 11
Acinetobacter baumannii	M6226989	Serratia marcescens	SM 12
Acinetobacter baumannii	F5727811	Serratia marcescens	SM 13
Acinetobacter baumannii	M6004145	Serratia marcescens	M6315510
Acinetobacter baumannii	X3812952	Serratia marcescens	X3925583 # 1
Acinetobacter baumannii	F5832616	Serratia marcescens	X3925583 # 2
Acinetobacter baumannii	F5835440	Acinetobacter baumannii	T6542349
Acinetobacter baumannii	S4292042	Acinetobacter baumannii	H6432894
Acinetobacter baumannii	X3845805	Acinetobacter baumannii	M6324995
Acinetobacter baumannii	T6172219	Acinetobacter baumannii	H6343630
Acinetobacter baumannii	H6078005	Acinetobacter baumannii	S4510581
Acinetobacter baumannii	F5852249	Acinetobacter baumannii	X4075444
Acinetobacter baumannii	F5847155	Acinetobacter baumannii	F6201782
Acinetobacter baumannii	M6113993	Acinetobacter baumannii	H6468736 # 1
Acinetobacter baumannii	H6094261	Acinetobacter baumannii	H6468736 # 2
Acinetobacter baumannii	S4326066	Acinetobacter baumannii	H6509069
Acinetobacter baumannii	H6504483	Acinetobacter baumannii	H6668538
Acinetobacter baumannii	F6275094	Acinetobacter baumannii	F6413360
Acinetobacter baumannii	W6371925	Acinetobacter baumannii	H6689003 # 1
Acinetobacter baumannii	S4489171-1	Acinetobacter baumannii	H6689003 # 2
Acinetobacter baumannii	M6368166	Acinetobacter baumannii	H6688979
Acinetobacter baumannii	W6393209	Acinetobacter baumannii	F6435319 # 1
Acinetobacter baumannii	M6391197	Acinetobacter baumannii	F6435319 # 2
Acinetobacter baumannii	T6520248	Acinetobacter baumannii	S4715753
Acinetobacter baumannii	H6417812	Acinetobacter baumannii	S4715756
Acinetobacter baumannii	S4542196	Acinetobacter baumannii	S4720954
Acinetobacter baumannii	T6530325	Acinetobacter baumannii	M6716608
Acinetobacter baumannii	H6449923	Acinetobacter baumannii	W6741369
Acinetobacter baumannii	H6465612 # 1	Acinetobacter baumannii	H6708536
Acinetobacter baumannii	H6465612 # 2	Acinetobacter baumannii	T6837121
Acinetobacter baumannii	H6467111	Acinetobacter baumannii	T6844157
Acinetobacter baumannii	F6212404	Acinetobacter baumannii	W6788536
Acinetobacter baumannii	X4108289	Acinetobacter baumannii	W6788537
Acinetobacter baumannii	F6248736	Acinetobacter baumannii	W6798196
Acinetobacter baumannii	H6522237	Acinetobacter baumannii	T6912170
Acinetobacter baumannii	F6259710	Acinetobacter baumannii	S4820321
Acinetobacter baumannii	M6557931	Acinetobacter baumannii	T6960905
Acinetobacter baumannii	M6570364	Acinetobacter baumannii	W6892187
Escherichia coli	YDC107 YD	Acinetobacter baumannii	X4370779
Escherichia coli	YDC107 TBD	Acinetobacter baumannii	W6640817
Escherichia coli	CA11	Acinetobacter baumannii	T6781787
Klebsiella pneumoniae	C2	Acinetobacter baumannii	M6727536-1
Klebsiella pneumoniae	D7	Acinetobacter baumannii	X4324443
Pseudomonas aeruginosa	PAO1	Acinetobacter baumannii	S4825574
Staphylococcus aureus	MRSA DOH 040	Acinetobacter baumannii	S4823762
Staphylococcus aureus	MRSA DOH 075	Acinetobacter baumannii	W6910684
Enterococcus	VRE 24670	Acinetobacter baumannii	M6634593
Enterococcus	VRE 26692	Acinetobacter baumannii	S4892351
Acinetobacter baumannii	1A3 TBD	Acinetobacter baumannii	X4230972
Acinetobacter baumannii	1F8 TBD	Acinetobacter baumannii	M6594033
Acinetobacter baumannii	M6547155	Acinetobacter baumannii	S4699435
Acinetobacter baumannii	F6295668	Acinetobacter baumannii	W6711824 # 1
Acinetobacter baumannii	T6705170	Acinetobacter baumannii	W6711824 # 2
Acinetobacter baumannii	F6391360	Acinetobacter baumannii	X4206386
Acinetobacter baumannii	S4684993	Acinetobacter baumannii	F6316522
Acinetobacter baumannii	S4686203	Acinetobacter baumannii	F6388319
Acinetobacter baumannii	M6654224	Acinetobacter baumannii	W6720874
Acinetobacter baumannii	W6693747	Acinetobacter baumannii	F6504088
Acinetobacter baumannii	W6922298	Acinetobacter baumannii
Acinetobacter baumannii	X4369531	Acinetobacter baumannii	M7258938
Acinetobacter baumannii	F6636182	Acinetobacter baumannii	H7234039
Acinetobacter baumannii	H6901665	Acinetobacter baumannii	T7395013
Acinetobacter baumannii	F6652813	Acinetobacter baumannii	X4624820
Acinetobacter baumannii	S4887595	Acinetobacter baumannii	H7283745
Acinetobacter baumannii	S4887596	Acinetobacter baumannii	S5146483
Acinetobacter baumannii	M7001534	Acinetobacter baumannii	S5144766
Acinetobacter baumannii	T7118427	Acinetobacter baumannii	S5144767
Acinetobacter baumannii	W7026767	Acinetobacter baumannii	S5153022
Acinetobacter baumannii	W7027329	Acinetobacter baumannii	F7045731
Acinetobacter baumannii	H7041121	Acinetobacter baumannii	F7044161
Acinetobacter baumannii	M7082089	Acinetobacter baumannii	S5175684
Acinetobacter baumannii	M7082123	Acinetobacter baumannii	H7342951
Acinetobacter baumannii	H7062449	Acinetobacter baumannii	F7071176
Acinetobacter baumannii	M7108041	Acinetobacter baumannii	F7077571
Acinetobacter baumannii	T7202985	Acinetobacter baumannii	F7077571
Acinetobacter baumannii	T7244103	Acinetobacter baumannii	F7071329
Acinetobacter baumannii	H7110321	Acinetobacter baumannii	S5190099
Acinetobacter baumannii	H7104234	Acinetobacter baumannii	X4689437
Acinetobacter baumannii	M7156070	Acinetobacter baumannii	X4689555
Acinetobacter baumannii	F6871068	Acinetobacter baumannii	M7426099
Acinetobacter baumannii	W7197258	Acinetobacter baumannii	T7513368
Acinetobacter baumannii	W7208924	Acinetobacter baumannii	T7529070
Acinetobacter baumannii	W7210606	Acinetobacter baumannii	T7513462
Acinetobacter baumannii	F6926143	Acinetobacter baumannii	H7398342
Acinetobacter baumannii	H7182108	Acinetobacter baumannii	M7435333
Acinetobacter baumannii	H6879046	Acinetobacter baumannii	H7398342
Acinetobacter baumannii	M6945349	Acinetobacter baumannii	T7580580
Acinetobacter baumannii	H6934427	Acinetobacter baumannii	H7449015
Acinetobacter baumannii	F6715105	Acinetobacter baumannii	H7449650
Acinetobacter baumannii	T7187783	Acinetobacter baumannii	F7174333
Acinetobacter baumannii	F6843354	Acinetobacter baumannii	T7570091
Acinetobacter baumannii	F6847922	Acinetobacter baumannii	T7570089
Acinetobacter baumannii	M7150740	Acinetobacter baumannii	M7498119
Acinetobacter baumannii	T7268129	Acinetobacter baumannii	T7196382
Acinetobacter baumannii	M7191688	Acinetobacter baumannii	X4754725
Acinetobacter baumannii	M7211623	Acinetobacter baumannii	S5301575
Acinetobacter baumannii	T7315372	Acinetobacter baumannii	M7536545
Acinetobacter baumannii	W6959400	Acinetobacter baumannii	W7581338
Acinetobacter baumannii	T7150606	Acinetobacter baumannii	M7574228
Acinetobacter baumannii	T7286950	Acinetobacter baumannii	M7576584
Acinetobacter baumannii	T7364864	Acinetobacter baumannii	F7382345
Acinetobacter baumannii	H7229162	Acinetobacter baumannii	T7852665
Acinetobacter baumannii	M7282089	Acinetobacter baumannii	F7418055
Acinetobacter baumannii	T7450967	Acinetobacter baumannii	S5434534
Acinetobacter baumannii	H7308283	Acinetobacter baumannii	T7876307
Acinetobacter baumannii	X4652199	Acinetobacter baumannii	S5462569
Acinetobacter baumannii	F7053276	Acinetobacter baumannii	S5476955-1
Acinetobacter baumannii	T7469180	Acinetobacter baumannii	S5476955-2
Acinetobacter baumannii	H7342303	Acinetobacter baumannii	F7491014
Acinetobacter baumannii	H7332154 # 1	Acinetobacter baumannii	X4952534
Acinetobacter baumannii	H7332154 # 2	Acinetobacter baumannii	T7943002
Acinetobacter baumannii	H7342303 # 2	Acinetobacter baumannii	T8009201
Acinetobacter baumannii	S5189078	Acinetobacter baumannii	H7869473
Acinetobacter baumannii	X4675691	Acinetobacter baumannii	H7555054
Acinetobacter baumannii	F7096051	Acinetobacter baumannii	T7717740
Acinetobacter baumannii	F7096452	Acinetobacter baumannii	W7615302
Acinetobacter baumannii	W7519025	Acinetobacter baumannii	S5342757
Acinetobacter baumannii	X4785831	Acinetobacter baumannii	T7750534
Acinetobacter baumannii	T7693515	Acinetobacter baumannii	T7750534
Acinetobacter baumannii	T7693524	Acinetobacter baumannii	H7598358
Acinetobacter baumannii	M7374618 # 1	Acinetobacter baumannii	X4838376
Acinetobacter baumannii	M7374618 # 2	Acinetobacter baumannii	T7766780
Acinetobacter baumannii	W7553904	Acinetobacter baumannii	W7671817
Acinetobacter baumannii	W7578283	Acinetobacter baumannii	H7635547
Acinetobacter baumannii	F6948309	Acinetobacter baumannii	M7709402
Acinetobacter baumannii	W7290980	Acinetobacter baumannii	T7820160
Acinetobacter baumannii	M7310854	Acinetobacter baumannii	F7390009
Acinetobacter baumannii	M7392235	Acinetobacter baumannii	W7734369
Acinetobacter baumannii	W7484162	Acinetobacter baumannii	S5459386
Acinetobacter baumannii	W7601810	Acinetobacter baumannii	S5461928
Acinetobacter baumannii	F7271515	Acinetobacter baumannii	X4936260
Acinetobacter baumannii	S5335610	Acinetobacter baumannii	M7316381
Acinetobacter baumannii	H7579564	Acinetobacter baumannii	S5495509
Acinetobacter baumannii	X4831716	Acinetobacter baumannii	M7838140
Acinetobacter baumannii	F7298304	Acinetobacter baumannii	W7854006
Acinetobacter baumannii	H7610715	Acinetobacter baumannii	T7973820
Acinetobacter baumannii	T7772783	Acinetobacter baumannii	W7891295
Acinetobacter baumannii	M7712644	Acinetobacter baumannii	H7842805
Acinetobacter baumannii	M7712658	Acinetobacter baumannii	M7877907
Acinetobacter baumannii	T7822340	Acinetobacter baumannii	T8000438
Acinetobacter baumannii	H7685900	Acinetobacter baumannii	H7872553
Acinetobacter baumannii	H7693024	Acinetobacter baumannii	M7896154
Acinetobacter baumannii	M7914463	Streptococcus mitis	POS 4489
Acinetobacter baumannii	W7930548	Streptococcus mitis	POS 5586
Acinetobacter baumannii	F7316875	Streptococcus mutans	POS 5593
Acinetobacter baumannii	T7796673	Streptococcus mutans	POS 1260
Acinetobacter baumannii	T7850239	Streptococcus pneumoniae	POS 10164
Acinetobacter baumannii	W7763340	Streptococcus pneumoniae	POS 6892
Acinetobacter baumannii	M7837667	Staphylococcus haemolyticus	POS 8764
Acinetobacter baumannii	F7518628	Staphylococcus lugdunensis	POS 10768
Candida albicans	YST 1032	Staphylococcus lugdunensis	POS 8659
Candida albicans	YST 1369	Streptococcus mitis	POS 4489
Candida albicans	YST 1862	Streptococcus mitis	POS 5586
Escherichia coli	ENF 18187	Streptococcus mutans	POS 5593
Enterobacter aerogenes	ENF 10856	Streptococcus mutans	POS 1260
Enterobacter aerogenes	ENF 11218	Streptococcus pneumoniae	POS 10164
Enterobacter aerogenes	ENF 11237	Streptococcus pneumoniae	POS 6892
Klebsiella oxytoca	ENF 3950	Streptococcus pneumoniae	POS 6289
Klebsiella oxytoca	ENF 4321	Streptococcus sanguinis	POS 5589
Klebsiella oxytoca	ENF 11686	Streptococcus sanguinis	POS 4696
Klebsiella pneumoniae	ENF 16491	Strains identified in blood bottles
Klebsiella pneumoniae	ENF 18027	Escherichia coli	W3110
Pseudomonas aeruginosa	ENF 17948	Pseudomonas aeruginosa	PAO1
Staphylococcus epidermidis	POS 6544	Acinetobacter baumannii	1I7
Staphylococcus epidermidis	POS 10235	Klebsiella pneumoniae	B6
Staphylococcus haemolyticus	POS 10866	Staphylococcus aureus	M2
Staphylococcus haemolyticus	POS 8764	Staphylococcus aureus	NRS123
Staphylococcus lugdunensis	POS 10768
Staphylococcus lugdunensis	POS 8659

The following references are cited herein:

• 1. El Hamidi et al., J. Lipid Res., 2005, 46:1773-1778.
• 2. Tirsoaga et al. J Lipid Res. 2007, 48(11):2419-27.

The present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present invention.

Claims

1. A method for rapidly identifying a microbe, comprising: obtaining a biological sample from a subject;determining, via spectrometry, a molecular mass profile of microbial lipids; andcomparing the molecular mass profile of the lipids from the microbe with a molecular mass profile of lipids from a known microbe wherein an identical profile indicates the identity of the microbe in the biological sample.

2. The method of claim 1, further comprising: isolating the microbe from the biological sample.

3. The method of claim 1, wherein the determining step comprises: extracting lipids from the microbe prior to the spectrometry; orperforming spectrometry on microbial cells.

4. The method of claim 1, wherein the spectrometry is mass spectrometry, tandem mass spectrometry or ion mobility spectrometry.

5. The method of claim 1, wherein the lipid is lipid A, Lipoteichoic Acid, a glycolipid, or cardiolipin.

6. The method of claim 1, wherein the microbe is a pathogen, a non-pathogen or a commensal bacterium.

7. The method of claim 6, wherein the pathogen is selected from the group consisting of Acinetobacter; Actinomyces, Arthrobacter, Burkholderia, Bacillus, Bacteroides, Bordetella, Borrelia, Brevundimonas, Brucella, Candida, Clostridium, Corynebacterium, Campylobacter, Deinococcus, Escherichia, Enterobacter, Enterococcus, Erwinia, Eubacterium, Exiguobacterium, Flavobacterium, Francisella, Gluconobacter, Helicobacter, Intrasporangium, Janthinobacterium, Klebsiella, Kingella, Legionella, Leptospira, Mycobacterium, Moraxella, Micrococcus, Neisseria, Oscillospira, Proteus, Pseudomonas, Providencia, Paenibacillus, Rickettsia, Rhodococcus, Roseomonas, Rothia, Salmonella, Serratia, Staphylococcus, Shigella, Spirillum, Streptococcus, Stenotrophomonas Treponema, Ureaplasma, Vibrio, Wolinella, Wolbachia, Xanthomonas, Yersinia, and Zoogloea.

8. The method of claim 1, wherein the microbe is a Gram-negative bacterium and the lipid is lipid A, a glycolipid or cardiolipin.

9. The method of claim 1, wherein the microbe is a Gram-positive bacterium and the lipid is Lipoteichoic Acid, a glycolipid or cardiolipin.

10. The method of claim 1, wherein the microbe is a fungus and the lipid is a glycolipid or cardiolipin.

11. The method of claim 1, wherein the biological sample is blood, urine, stool, serum, wound effluent or bronchoalveolar lavage fluid.

12. A method for rapidly identifying a pathogenic bacterium in a blood sample comprising: obtaining the blood sample from a subject;extracting lipids from the bacterial pathogen at zero passage;determining, via spectrometry, a molecular mass profile of the extracted lipids; andcomparing the molecular mass profile of the extracted lipids with a molecular mass profile of lipids from a known pathogenic bacterium wherein an identical profile indicates the identity of the pathogenic bacteria.

13. The method of claim 12, further comprising: isolating the pathogenic bacterium from the blood sample.

14. The method of claim 12, wherein the spectrometry is mass spectrometry, tandem mass spectrometry or ion mobility spectrometry.

15. The method of claim 12, wherein the pathogenic bacterium is selected from the group consisting of Acinetobacter, Actinomyces, Arthrobacter, Burkholderia, Bacillus, Bacteroides, Bordetella, Borrelia, Brevundimonas, Brucella, Clostridium, Corynebacterium, Campylobacter, Deinococcus, Escherichia, Enterobacter, Enterococcus, Erwinia, Eubacterium, Exiguobacterium, Flavobacterium, Francisella, Gluconobacter, Helicobacter, Intrasporangium, Janthinobacterium, Klebsiella, Kingella, Legionella, Leptospira, Mycobacterium, Moraxella, Micrococcus, Neisseria, Oscillospira, Proteus, Pseudomonas, Providencia, Paenibacillus, Rickettsia, Rhodococcus, Roseomonas, Rothia, Salmonella, Serratia, Staphylococcus, Shigella, Spirillum, Streptococcus, Stenotrophomonas Treponema, Ureaplasma, Vibrio, Wolinella, Wolbachia, Xanthomonas, Yersinia, and Zoogloea.

16. The method of claim 12, wherein the pathogenic bacterium is a Gram-negative bacterium and the lipid is lipid A, a glycolipid or cardiolipin or the pathogenic bacterium is Gram-positive bacterium and the lipid is Lipoteichoic Acid, a glycolipid or cardiolipin.

17. A method for identifying one or more antimicrobial drugs effective to treat a microbial strain in a subject in need of such treatment, comprising: obtaining a biological sample from the subject;extracting lipids from microbes in the sample,performing a spectrographic analysis of the extracted lipids to obtain a molecular mass profile thereof;comparing the extracted lipids profile with a library of known lipid profiles of strains of pathogenic microbes to identify the strain of pathogenic microbe in the biological sample; andidentifying one or more antimicrobial drugs effective to treat the identified microbial strain.

18. The method of claim 17, wherein the performing step comprises analysis via mass spectrometry, tandem mass spectrometry or ion mobility spectrometry.

19. The method of claim 18, wherein the spectrographic analysis of lipids differentiates among pathogenic microbes at the genus, species, sub-species or strain level.

20. The method of claim 17, wherein the pathogenic microbe is a Gram-negative bacterium, a Gram-positive bacterium or a fungus.

21. The method of claim 20, wherein the Gram-negative bacterial lipid is lipid A, a glycolipid or cardiolipin, the Gram-positive bacterial lipid is Lipoteichoic Acid, a glycolipid or cardiolipin and the fungal lipid is a glycolipid precursor of one or both of lipid A or Lipoteichoic Acid or a cardiolipin.

22. The method of claim 17, wherein the biological sample is blood, urine, stool, serum, wound effluent or bronchoalveolar lavage fluid.